Top 100 drugs – CRI Report https://www.cri-report.com market research vender! Mon, 02 Aug 2021 12:37:10 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Top 100 drugs – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Sildenafil Market, 2018-2022 https://www.cri-report.com/investigation-report-on-chinas-sildenafil-market-2018-2022/ Wed, 12 Sep 2018 02:50:48 +0000 https://www.cri-report.com/product/import-placeholder-for-1809336/ The market share of Pfizer's Viagra, either by sales volume or by sales value, exceeded 90% in 2017. However, it will decrease as China-made counterparts are launched.

The post Investigation Report on China’s Sildenafil Market, 2018-2022 first appeared on CRI Report.

]]> According to statistics, more than 60% of Chinese men aged 35 and above suffer from sexual dysfunction.
Sildenafil is developed by Pfizer to treat penile erectile dysfunction, pulmonary hypertension, mountain sickness, etc. Pfizer’s application for Viagra’s patent was approved by China’s State Intellectual Property Office in 1994. According to the patent law of China, the patent should be valid for 20 years till 2014. After the expiration of the patent, pharmaceutical companies can produce Sildenafil as long as they have obtained the approval. Therefore, Chinese manufacturers began to launch Sildenafil in 2014. CRI’s market investigation shows that China’s Sildenafil market is dominated by Pfizer’s Viagra, Baiyunshan’s Jinge and Yabang Aipusen’s Wanfeile. The market share of Pfizer’s Viagra, either by sales volume or by sales value, exceeded 90% in 2017. However, it will decrease as China-made counterparts are launched.
The number of erectile dysfunction patients will continue to rise in the next few years as the economy develops, the lifestyle changes, and psychological pressures increase in China. Furthermore, Sildenafil is becoming more affordable with the rise of income in China. The sales value of Sildenafil exceeded CNY 30 million in 2017, and the market will continue to grow in the next few years.

Topics Covered:
– Development environment of China’s Sildenafil market
– Sales of Sildenafil in China
– Competition pattern of China’s Sildenafil market
– Prices of Sildenafil in China’s Hospitals
– Driving forces and market opportunities for China’s Sildenafil market
– Prospect of China’s Sildenafil market

The post Investigation Report on China’s Sildenafil Market, 2018-2022 first appeared on CRI Report.

]]> Investigation Report on China’s Lamivudine Market, 2018-2022 https://www.cri-report.com/investigation-report-on-chinas-lamivudine-market-2018-2022/ Wed, 12 Sep 2018 02:50:45 +0000 https://www.cri-report.com/product/import-placeholder-for-1809335/ At the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China. In addition, a large number of people infected with HIV and AIDS patients have not been discovered. Meanwhile, over 90 million people in China are infected with the hepatitis B virus. Lamivudine is a major drug against the hepatitis B virus and AIDS in China. The Chinese government offers it to AIDS patients for free. Lamivudine is a nucleoside analog as well as an antiviral drug. In 1998, the FDA first approved…

The post Investigation Report on China’s Lamivudine Market, 2018-2022 first appeared on CRI Report.

]]> At the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China. In addition, a large number of people infected with HIV and AIDS patients have not been discovered. Meanwhile, over 90 million people in China are infected with the hepatitis B virus.
Lamivudine is a major drug against the hepatitis B virus and AIDS in China. The Chinese government offers it to AIDS patients for free. Lamivudine is a nucleoside analog as well as an antiviral drug. In 1998, the FDA first approved Lamivudine as a treatment for hepatitis B. The State Food and Drug Administration (SFDA) approved the drug to be imported to China for the treatment of hepatitis B. In 1999, GlaxoSmithKline started to sell its original Lamivudine in the trade name “Heptodin” in China. More than 2 million hepatitis B patients and an unknown number of HIV-infected patients and AIDS patients are taking Heptodin in China.
By the end of 2017, more than 10 enterprises had been approved to produce Lamivudine tablets or capsules.
Lamivudine developed rapidly after it entered China. The sales volume reached CNY 307 million in 2012, declined from 2013 and fell to about CNY 159 million in 2017. The market is dominated by GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd., Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical Co., Ltd. and Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd. has the largest market share. Its sales value exceeded CNY 100 million in 2017, taking up a market share close to 67%.
Considering the large number of hepatitis B and AIDS patients in China, it is expected that the market size of China’s Lamivudine market will continue to grow.

Topics Covered:
– Development environment of China’s Lamivudine market
– Size of China’s Lamivudine market
– Competition pattern of China’s Lamivudine market
– Prices of Lamivudine in China
– Driving forces and opportunities for China’s Lamivudine market
– Prospect of China’s Lamivudine market from 2018 to 2022

The post Investigation Report on China’s Lamivudine Market, 2018-2022 first appeared on CRI Report.

]]>